Christopher Bichakjian

Professor and Chair

University of Michigan
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Comparison of t-TMB and CNV scores by clinicopathologic variables in overall cohort. Data shown as median (range) or n (%) for continuous and categorical variables, respectively. Wilcoxon Rank-Sum and Kruskal-Wallis tests used for comparison of categorical and continuous variables, respectively. Additionally, we saw no correlation between primary tumor Breslow depth (mm) and t-TMB (Pearson’s r = -0.131, [95% CI: - 0.412 – 0.173], p = 0.397) or CNV score (Pearson’s r = -0.102, [95% CI: - 0.387 – 0.201], p = 0.511). a Data for primary tumor LVI and Breslow depth available for 45 of 54 (83.3%) patients.

Year:

2025

Kaplan-Meier curves for MCC-specific survival by clinicopathologic variables. Patient sex (A), primary tumor site (B), AJCC 8th edition overall (C) and nodal (D) stage, tumor MCPyV status (E), and MCPyV physical state (for VP-MCC tumors) (F).

Year:

2025

Scatter plot illustrating the correlation between the number of MCPV alterations per tumor and the corresponding number of MCPV reads and Variant Allele Frequency (VAF) plots for all single nucleotide variants and insertions/deletions identified in the cohort.

Year:

2025

Merkel cell carcinoma (MCC) is an aggressive disease with poor survival outcomes and increasing incidence. There is a clear and present need for enhanced understanding of cellular mechanisms of tumorigenesis, validation of robust genetic signatures predictive of aggressive disease, and novel informatics tools to simplify analysis of Merkel cell polyomavirus (MCPyV)–host genome interactions. Genomic DNA was harvested from 54 MCC tumors for exome sequencing and in-depth genetic profiling of a 226-gene panel. We further developed a robust informatics package (MCPyViewer) optimized for MCPyV integration site analysis with graphical output to simplify usability for end users. Finally, we assessed the prognostic impact of specific genetic signatures on MCC-specific survival in our cohort. Our study included 54 patients ( n = 44 MCPyV positive), 11 (20.4%) of whom had died of MCC at last follow-up. Human genes altered at high frequency included LRP1B ( n = 10, 18.5%), FAT1 ( n = 9, 16.7%), KMT2D ( n = 9, 16.7%), and RB1 ( n = 7, 13.0%). In 36 of 44 (81.8%) MCPyV-positive tumors, we identified viral integration into the human genome with a median of two events per tumor. In six tumors, MCPyV integrated into Catalogue of Somatic Mutations in Cancer tier 1 or tier 2 cancer-related human genes. Implications: A combined genomics score incorporating tumor mutational burden and copy-number variation was strongly prognostic of MCC-specific survival controlling for lymph node metastases and tumor MCPyV status; thus, our study adds critical understanding to prognostic markers and tumorigenic mechanisms in MCC.

Year:

2025

Representative MCPyV integration events in MiOTO_4055 and MiOTO_4003 that fell within human oncogenes. Red arrow: MCPyV integration; Black segment: contigs assembled at integration events; Segments with black arrowhead: zoomed in contigs aligned to the human genome; Segments with red arrowhead: zoomed in contigs aligned to the MCPyV genome. Direction of segments indicate the strand of contigs aligned to. Note figure constructed using MCPyViewer.

Year:

2025

Survival analyses for prognostic genetic signatures in MCC cohort. A-B. Kaplan-Meier curves for MCC-specific survival by t-TMB category in N+ patients (A) and VP-MCC patients (B). Kaplan-Meier curves for MCC-specific survival by CNV score category in N+ patients (C) and VP-MCC patients (D).

Year:

2025

Summary of definitive treatment modalities for MCC patients in our cohort, stratified by stage. Data presented as n (%). a Including sentinel lymph node biopsy ± completion lymphadenectomy of regional lymphatic basin.

Year:

2025

Collaborators (5)

Ryan Mills

Professor

University of Michigan

UNITED STATES
View details

Kelly L. Harms

University of Michigan

UNITED STATES
View details

Matthew E. Spector

University of Pittsburgh Medical Center

UNITED STATES
View details

J. Chad Brenner

Director Head and Neck Oncology Program

University of Michigan

UNITED STATES
View details

Scott McLean

Clinical Associate Professor

University of Michigan

UNITED STATES
View details